Company news

Viridian Therapeutics, Inc. (NASDAQ:VRDN) news

Viridian Therapeutics, Inc. news releases on 6ix. Latest, Aug 6, 2026: Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter…

Viridian Therapeutics, Inc. (NASDAQ:VRDN) news

Press releases & updates

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Raymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Bambusa Therapeutics Appoints Todd James Chief Financial Officer

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Viridian Therapeutics Prepares for Transformational 2026

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference

Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology